VEGF antagonists are now widely used cancer therapeutics but predictive biomarkers of response or toxicity remain unavailable. In this study, we analyzed the effects of anti-VEGF therapy on tumor metabolism and therapeutic response using an integrated set of non-invasive imaging techniques, including bioluminescence metabolic imaging, 18-fluorodeoxyglucose PET and MRI imaging and spectroscopy. Our results revealed that anti-VEGF therapy caused a dramatic depletion of glucose and an exhaustion of ATP levels in tumors, although glucose uptake was maintained. These metabolic changes selectively accompanied the presence of large necrotic areas and partial tumor regression in highly glycolytic tumors. Additionally, we found that the central metabolic protein kinase AMPK -a cellular sensor of ATP levels that supports cell viability in response to energy stress -was activated by anti-VEGF therapy in experimental tumors.
INTRODUCTION
Tumor vascular targeting has been validated as a therapeutic concept with the approval of several drugs that block the vascular endothelial growth factor (VEGF)-VEGF receptor pathway (1, 2) . However, both pre-clinical models and clinical trials have shown that benefits from first-generation angiogenesis inhibitors are generally short-term, due to the development of intrinsic as well as acquired resistance (3) . A major challenge in the field is therefore to identify biomarkers of efficacy and toxicity that guide the selection of patients who are most likely to benefit from treatment (4, 5) .
Various types of response to anti-angiogenic drugs such as sunitinib or bevacizumab have been observed in cancer patients. In some cases, patients present a decrease in tumor volume by more than 33%, qualifying them as partial responders according to RECIST criteria. In other patients, however, significant changes are observed only in tumor density with no decrease in size. This is often associated with central tumor cavitation and necrosis (6) . While this clinical observation suggests that anti-angiogenic therapy may cause severe energy imbalance in certain tumors, it is currently unknown whether molecular or metabolic features of tumor cells could be involved in the type of pathologic response to VEGF-targeting drugs or could predict efficacy. Pre-clinical models may help to solve these issues.
In experimental tumors, anti-VEGF drugs typically prune the newly formed vasculature, thus reducing microvessel density, blood flow and perfusion and eventually increasing the level of intratumoral hypoxia (7) (8) (9) . Although in patients mechanisms might be more complex, considering that VEGF neutralization has therapeutic efficacy mainly when combined with conventional chemotherapy (10), Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on May 5, 2011; DOI: 10.1158/0008-5472. it is currently held that following an initial time window of "vascular normalization", regression of tumor vasculature occurs leading to increased hypoxia (11) . Less well understood is whether hypoxia eventually leads to tumor starvation. On one hand, hypoxia can exert both anti-proliferative effects or induce cancer cell death depending on specific genetic features of tumor cells (12) (13) (14) . On the other hand, hypoxia can also favor invasion and metastasis, as an evasive mechanism to anti-angiogenic therapy (reviewed in: (15) ).
Although it is usually granted that anti-angiogenic drugs cut oxygen supply into tumors, surprisingly less is known about other metabolic perturbations induced by VEGF blockade in the tumor microenvironment.
In a previous study, we identified ovarian cancer cells endowed with different glycolytic phenotypes and correlated this feature with resistance or sensitivity to severe hypoxia in vitro (12) . The great variations in glucose demand that we observed in tumor cell lines possibly reflect their genetic heterogeneity and, importantly, this has also been observed in patients affected by the same tumor type, mainly by 18fluorodeoxyglucose (FDG) positron-emission tomography (PET) (16, 17) .
Xenografts obtained from these cells have been analyzed here to investigate the effects of VEGF neutralization on glucose metabolism by using for the first time an integrated imaging approach which included metabolic bioluminescence imaging, FDG PET and magnetic resonance spectroscopy (MRS) analysis. mixed at 4°C with liquid Matrigel (Becton-Dickinson; Franklin Lakes, NY). Tumor volume (mm 3 ) was calculated as previously reported (12) . Anti-human VEGF mAb (A4.6.1) was administered intraperitoneally (i.p.) at 100 μg/dose every 2 days, and mice were sacrificed 48 h after the third treatment. Control mice received i.p.
injections of PBS.
Histology and immunohistochemistry. Quantification of necrosis was carried out by calculating the percentage of the necrotic area in the entire tumor section by using a light microscope equipped with digital camera and MODEL software (Leica Microsystems, Wetzlar, Germany). pAMPK monoclonal (1:300, #2535S) and pACC polyclonal (1:400, #3661S) antibodies from Cell Signaling Technology (Beverly, MA) were used for immunohistochemistry. Scoring of pAMPK or pACC expression was performed by an experienced pathologist (G.E.) at a magnification of x100, based on the Quick Score Method (18) . Immuno-reactivity was scored semi-quantitatively for both the intensity and the proportion of cells staining: intensity was given scores 0-3 (no staining = 0; light staining = 1; moderate staining = 2; strong staining = 3) and proportion was given scores 1-6 (0-4% = 1; 5-20% = 2; 21-40% = 3; 41-60% = 4; 61-80% = 5; 81-100% = 6). The two scores were multiplied to obtain the final result of 0-18. In evaluation of pACC staining in RIP-Tag2 tumor sections, due to immunodetection heterogeneity among samples, the intensity of the normal tissue in each tissue section was taken as a To determine whether these metabolic differences were conserved in vivo, we generated s.c. xenografts and characterized them by magnetic resonance imaging between the two models: OC316 tumors were characterized by a prominent central necrotic core, whereas IGROV-1 tumors had several small and diffuse necrotic areas (Suppl. Fig. 1C ). Following MRS analysis, lactate was observed in all OC316 tumors (n = 3), and in 50% of the IGROV-1 xenografts analyzed (n = 4).
Mean lactate concentrations were 38.2 ± 8.3 mM in OC316 tumors and 1.6 ± 0.1 mM in IGROV1 tumors (Suppl. Fig. 1D ). Finally, quantitative PCR analysis indicated higher expression levels of GAPDH, HKII, and LHDA in OC316 compared to IGROV-1 tumors (Suppl. Fig. 1E ). In summary, these findings indicate that OC316 and IGROV-1 are prototypes of tumors with markedly different glycolytic phenotypes.
Outcome of anti-VEGF therapy in tumors with different metabolic
properties. We subsequently treated OC316 and IGROV-1 xenografts with A4.6.1, a human VEGF neutralizing mAb bearing the same CDR region as bevacizumab (22) . A significant reduction in tumor size was observed in OC316 but not in IGROV-1 tumors after 6 days of treatment (Fig. 1A) . As expected, microvessel density (MVD) was significantly reduced after anti-VEGF treatment in all tumors (Fig. 1B) , and this was associated with a marked increase in hypoxic areas, as shown by quantification of pimonidazole adducts (Fig. 1C) , and hypoxia inducible factor (HIF)-1α levels (Suppl. Fig. 2 ). Histological analysis showed large necrotic areas within OC316 tumors treated with A4.6.1, whereas minimal changes were measured in IGROV-1 tumors (Fig. 1D) . This association between glycolytic phenotype and type of pathologic response to anti-VEGF therapy was not unique to the OC316/IGROV-1 pair. In fact, similar results were also seen after A4.6.1 administration to mice bearing Kyse-30 and OE19-derived tumors, formed by highly glycolytic and poorly glycolytic oesophageal cancer cells, respectively (Suppl. Fig. 3 ).
The effects of VEGF neutralization in tumors were further documented by MRI techniques. The apparent diffusion coefficient (ADC) value is often correlated with tumor cellularity, and in experimental tumors an elevated ADC value has been correlated with the necrotic fraction (23) . Quantitative MRI analysis showed ADC values of 8.0 ± 3.8 and 7.3 ± 4.1 x 10 -4 mm 2 /s (mean ± SD) for the OC316 and IGROV1 xenografts, respectively, which were in good agreement with those recently measured in patients with ovarian carcinoma (24) . Short course anti-VEGF treatment was associated with changes in spectral profiles and ADC distributions. Treated OC316 tumors had a higher necrotic fraction compared to controls, as determined by an increase in ADC mean value (9.0 ± 4.3), due to an increase in the right wing of the ADC distribution ( Fig. 2A) . Differences in the spectral profile were also found, which could reflect changes in tumor environment (i.e. pH) and/or altered metabolism (Fig. 2B) . The identity of these alterations remains so far unknown. Twenty four hours after the end of treatment lactate was detected in all tumours (3/3, 48 ± 6 mM). On the other hand, treated IGROV-1 xenografts did not show any difference in the spectral profile with respect to untreated controls, while ADC distribution revealed a shift towards lower values in the treated group suggesting the presence of cell swelling (Suppl. (Fig. 3B) . Moreover, ATP levels were also markedly reduced after A4.6.1 treatment, both in OC316 and IGROV-1 tumors (Fig. 3C ). These findings show profound changes in glucose metabolism following acute VEGF neutralization in tumors.
Impact of anti-VEGF treatment on FDG uptake. PET imaging of OC316 tumors distinctly showed areas of reduced FDG uptake in the tumor center (Fig. 4A ).
These regions corresponds to tissue necrosis found at MRI analysis and in H&E stained tissue sections (Suppl. Fig. 1 ). For statistical analysis these necrotic regions have not been taken into account. In IGROV-1 tumors a rather homogeneous uptake was found (Fig. 4A) . In these samples, FDG uptake normalized to the viable tumor volume was independent from anti-VEGF treatment as shown by the time activity curves (Fig. 4B) . The mean relative FDG uptake in the time interval from 10 to 30 min after tracer injection was 173 ± 12% in A4.6.1 treated mice and 175 ± 12% in control tumors (n.s.). However, in OC316 tumors treated with the anti-VEGF antibody PET imaging showed a significant higher glucose uptake as compared to untreated controls (Fig. 4B) .
The mean activity between 10' and 30' was 191 ± 11% (A4.6.1 treated) versus 150 ± 8% (control) (P<0.01). Altogether, these results indicate that glucose uptake is 
14 not compromised by anti-VEGF therapy, suggesting that the low glucose levels measured in tumors by bioluminescence-based metabolic imaging might depend on accelerated glucose consumption rather than impaired delivery.
VEGF-targeting drugs induce AMPK activation in experimental tumors.
AMPK is a cellular sensor that contributes to maintain the steady-state level of intracellular ATP (25) . Since anti-VEGF treatment lowered both glucose and ATP in vivo (Fig. 3) , we hypothesized that it might activate the AMPK pathway.
Staining with an anti-pAMPK Ab disclosed variable AMPK activation in A4.6.1-treated tumors, showing much more intense expression of pAMPK in IGROV-1 compared with OC316 tumors (Fig. 5A) . Phosphorylation of acetyl-coenzyme A carboxylase (ACC), a key target of AMPK (26) , was strongly increased in IGROV-1 tumors treated with anti-VEGF, compared to controls (Fig. 5B) . In line with results of anti-pAMPK staining, OC316 tumors had very weak pACC signal, and this did not change in samples treated with anti-VEGF mAb (Fig. 5B) . Moreover, treatment of IGROV-1 xenografts with vandetanib -an inhibitor of VEGFR, EGFR and RET tyrosine kinases [reviewed in: (27) ] -markedly increased pACC staining, further validating these findings (Fig. 5C) Finally, strong pACC reactivity was also observed in RIP-Tag2 tumors treated either short-or long-term with DC101, an anti-VEGFR Ab (28), compared to controls (Fig. 5D ), indicating that increased AMPK activation can occur as a consequence of VEGF blockade also in transgenic tumor models. 
pAMPK levels in IGROV-1 but not OC316 cells following cultivation in the absence of glucose both under normoxic and hypoxic conditions (Suppl. Fig. 5A ).
Analysis of pACC levels confirmed these findings, indicating strong ACC phosphorylation in IGROV-1 cells following glucose starvation, whereas pACC was only slightly increased in OC316 cells under the same experimental conditions (Suppl. Fig. 5A ). To corroborate these results, IGROV-1 and OC316 cells were cultivated in the presence of canonical AMPK activators. AICAR, a direct AMPK activator (26) , was able to activate AMPK in IGROV-1 but only barely in OC316 cells, as evaluated by immunoblotting analysis of pAMPK levels (Suppl. Since AMPK is activated by LBK1 (29), we investigated expression levels of this kinase in tumor cells. Results show that LBK1 is expressed at apparently similar levels both in IGROV-1 and OC316 cells; in contrast, LKB1 was absent in HeLa cells, which are known to lack this kinase (30) (Suppl. Fig 6A) .
Immunofluorescence analysis, however, disclosed that the pattern of LKB1 intracellular staining was partially different in IGROV-1 compared to OC316 cells.
In fact, LKB1 was invariably detected both in the cytoplasm and the nuclei of IGROV-1 cells, whereas 30.11 ± 8.68% OC316 cells lacked cytoplasmic staining (Suppl. Fig. 6B ). Sequencing of LKB1 disclosed a G>A variation at nucleotide 958 of LKB1 exon 8 (Suppl. Fig. 6C ), which is predicted to introduce a valin to methionin change in a domain of LKB1 putatively involved in the formation of the multimeric complex of LKB1 with STRADα and MO25 (31) . Altogether, these findings indicate that the AMPK pathway is dis-functional in OC316 cells, likely due to altered intracellular distribution of its upstream activator LKB1. Moreover, AMPKα1 expression was also attenuated by 20-40% (Fig. 6A) . Western blot analysis confirmed the presence of reduced AMPK level in these cells (Fig.   6A ), referred to here as IGROV-1 shAMPKα2 cells. Proliferation (Suppl. Fig. 7 ) and viability ( Fig. 6B ) of IGROV-1 shAMPKα2 cells under standard culture conditions were similar to that of control cells, transduced with a scramble shRNA vector.
However, glucose starvation was associated with significantly higher death of IGROV-1 shAMPKα2 compared to control cells (Fig. 6B) . Intriguingly, attenuation of AMPKα2 was followed by a marked increase in glucose consumption and lactate production under normoxic conditions (Fig. 6C) , implying that AMPK levels modulate the glycolytic rate in IGROV-1 cells.
In vivo, xenografts derived from IGROV-1 shAMPKα2 cells developed at faster rates compared to controls (Fig. 6D ). Following treatment with A4.6.1, a significant increase in necrosis was measured in tumors formed by IGROV-1 shAMPKα2 cells, whereas no difference was measured in control tumors (Fig. 6D) . 
DISCUSSION
Here we investigated how metabolic parameters contribute to determine the pathologic response to VEGF blockade in tumor xenografts. A first conclusion is that the glycolytic rate in cultured cell lines and their level of "glucose addiction" are of paramount importance in determining the amount of necrosis caused by angiogenesis inhibition. Although it is well recognized that low glucose concentrations can be present in large solid tumors due to their compromised vascular functions (20, 33) , with regard to the effects of anti-angiogenic drugs, previous studies have mainly characterized changes in hypoxia, assuming that glucose would remain available due to its high diffusion capacity in tissues. Our metabolic imaging results clearly showed that VEGF blockade acutely perturbs glucose and ATP levels in xenografts. Since in PET experiments FDG uptake in A4.6.1 treated animals was either the same (IGROV-1) or even higher (OC316) than in untreated controls (Fig. 4B) , glucose supply does not seem to be impaired by short-term anti-VEGF treatment. The higher FDG uptake into A4.6.1-treated OC316 tumors may be the result of either a higher glucose consumption rate or the induction of GLUT transporters which facilitate cellular uptake. Both mechanisms may depend from hypoxia-induced HIF-1α accumulation, which was indeed detected in A4.6.1-treated tumors (Suppl. Fig. 2 ). Although PET findings may appear to contradict those of bioluminescence-based metabolic imaging, it should be stressed that one method measures glucose uptake and the other steady-state levels. Therefore, it is possible that glucose consumption in anti-VEGF treated animals exceeds the increased glucose uptake, resulting in lower steady-state levels of this metabolite. (Fig. 5) . AMPK is a central metabolic switch found in all eukaryotes that governs glucose and lipid metabolism in response to alterations in nutrients and intracellular energy levels, as well as cell polarity (29) . The serine-threonine kinase liver kinase B1 (LKB1), a known tumor suppressor, is a key upstream activator of AMPK (29) . Since AMPK is activated when intracellular levels of ATP decline and intracellular levels of AMP increase, such as during nutrient deprivation and hypoxia, a certain level of AMPK activation is commonly seen in solid tumors (34), and we also observed this in the peri-necrotic areas of our control xenografts (Fig. 5) . In our study, however, hypoxia did not activate AMPK in vitro unless tumor cells were grown under glucose starvation (Suppl. Fig. 5 ). Therefore, AMPK activation after VEGF blockade is not likely to depend directly on hypoxia but, rather, on the low glucose and ATP levels detected in tumors. Indeed, AMPK activation fits nicely with the results of bioluminescence imaging. AMPK deficiency promotes apoptosis in culture following treatment with energy stress-inducing agents (30, 35) , probably because cells cannot restore ATP levels. It is thus possible that defects We also noticed that AMPKα2 attenuation increased glucose consumption and lactate production by IGROV-1 cells, thus contributing to the Warburg effect. It was previously known that HIF1α and its target genes are up-regulated in LKB1-AMPK-and TSC-deficient fibroblasts, indicating that loss of any of these genes is sufficient to alter cell metabolism (37, 38) . In IGROV-1 cells, HIF1α activity measured by a luciferase-based reporter assay doubled following attenuation of AMPKa2 levels by shRNA (Suppl. Fig. 8 ), suggesting that HIF1α could in part contribute to the modulation of cell metabolism in this system. The observation that AMPK is dis-functional in OC316 cells may also in part explain their increased glycolytic phenotype compared with IGROV-1 cells, although we are aware that also other signalling pathways dis-regulated in cancer -including cmyc, KRAS, Akt, and p53 -may regulate glucose metabolism (39) . In this regard, it is important to stress that Akt phosphorylation at residues ser473 and thr308 was lower in OC316 compared to IGROV-1 cells (Suppl. Fig. 9 ). Thus, although it has been reported that cells with high Akt activity do not activate AMPK efficiently (40) , this mechanism is not likely involved in OC316 cells. This study clearly has translational implications both for ovarian cancer and other malignancies. Bevacizumab has therapeutic activity in ovarian cancer also as single agent (41, 42) and two large phase III clinical trials (GOG-218 and ICON7) are undergoing to establish whether it improves efficacy of standard chemotherapy (43, 44) . Our findings are potentially important for several reasons. 
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